A Trial For Developing Of Inactivated Pneumo-4 Vaccine By Using Of An Immunostimulatory Complex (ISCOM)

Document Type : Original Article

Authors

1 Veterinary Serum and Vaccine Research Institute, Abbassia, Cairo, Egypt.

2 Veterinary Serum and Vaccine Research Institute, Abbassia, Cairo, Egypt

Abstract

The current study was conducted for the developing the vaccinal product with patent name, Pneumo-4, a combined inactivated respiratory virus vaccine adjuvanted with al- hydragel using immunestimulatory complex (ISCOM) in the form of Quill-A saponin.
This study was performed by preparation of three formulae of Pneumo-4 vaccine (adjuvented with Al-hydra-gel) and pneumo-s (adjuvented with Quill-A saponin only) while the third was Pneumo-s gel. (adjuvented with Al-hydra-gel incorporated with Quill-A saponin).
For evaluation of the prepared vaccine formulae, testing of purity, safety as well as potency and using of laboratory animals and apparently healthy calves.
This study proved that the three formulae of the prepared vaccines were pure and fully safe to be used in calves without any local or systemic post vaccinal reaction.
 Serological investigation using serum neutralization test and ELISA revealed that the vaccinated calves developed serum neutralizing antibody against all fractions of the prepared vaccine. This study proved that the prepared formulae of vaccines (Pneumo-s gel) giving a long lasting duration of immunity extends up to 30 weeks post vaccination and higher than of the locally produced pneumo-4 vaccine which giving up to 24 weeks only.
The best of choice is the vaccine formulae, which contains Al-hydra-gel participated with Quill-A saponin, as it is a balanced formulae and being pure, fully safe and highly potent and is recommended for field application for bovine.

Main Subjects

Files

Share

How to cite

Statistics